logo-loader

Ergomed, Silence Therapeutics, Symphony Environmental Technologies at next forum

Last updated: 16:30 09 Jan 2015 GMT, First published: 17:30 09 Jan 2015 GMT

speech_100x72_54affead8cfac

Next Thursday we would be delighted if you could join us in Mayfair to hear from three fantastic AIM companies -  Silence Therapeutics (LON:SLN),  Symphony Environmental Technologies (LON:SYM) and Ergomed (LON:ERGO).

Each oversees very different projects but all four are united by their exciting and significant progress. 

To ensure you don't miss out on the event on January 15, secure your place HERE.

Silence Therapeutics shares have risen recently after a "significant" breakthrough with its gene expression technology. Investors will already be aware of the firm's gene silencing platform called siRNA. Put simply, this ‘switches off’ or silences genes producing too much protein. Now the firm has shown its technology can be used to put proteins back in where they are missing. It has been successfully deployed in animals to produce potentially therapeutic levels of protein. Cystic Fibrosis and Duchenne Muscular Dystrophe, the result of rare genetic deficiencies, are two of the ailments it could be used to treat. The company aims to move this technology into primate studies over the next 12 months. Silence had net cash of £22mln at end November, sufficient for two years.

Momentum is building behind Symphony Environmental Technologies whose additives make plastics smarter. New investor Somerston Environmental Technologies acquired 15mln shares in Symphony at a then 22% premium to the prevailing stock price, and chief executive Michael Laurier bought 750,000 new shares at the same price. It was part of a fundraise that brought in almost £1.6mln that will repay all high-cost debt and bankroll a commercial assault on three major markets. Symphony’s technology can render plastics bio-degradable, or antimicrobial and increasingly is also being used in the fight against counterfeiting. Symphony is operationally geared, which means a significant slug of any new sales will fall straight to the bottom line.

Ergomed is valued at just £41mln and is co-developing a range of potential blockbuster treatments. Originally a pure play contract research organisation (CRO) performing outsourced lab work for pharma and biotech firms, Ergomed also now has a hugely promising clinical services business. It partners with smaller developers to steer new drugs through the development process in return for a share in any successes. Three drugs are in phase III trials: Ganetespib for lung cancer, Multikine for head and neck cancer and Zoptarelin for endometrial cancer, while Lorediplon, to treat insomnia, is at the phase II stage. Ergomed is profitable and cash generative, traits that have burnished its credentials in a life sciences sector that has seen its share of disappointments. Rolf Stahel’s recent appointment as chairman, meanwhile, was both a huge coup and further validation of the strategy. He took Shire (LON:SHP) from an unknown private company to FTSE 100 constituent. Investors will be hoping Ergomed can emulate Shire’s progress.

The evening will end with a complimentary bar and an assortment of hot & cold canapes, giving you the opportunity to speak with the directors and other investors.

Please join us at 5:45pm to allow for a prompt 6pm start. Each company has around 30 minutes to give a short presentation and for Q&A. This will be followed by the 'Champagne Raffle' where four guests will win a bottle each. The evening will end with a drinks reception with canapés.

Oriole Resources outlines 2023 achievements and future exploration plans

Oriole Resources PLC (AIM:ORR) CEO Tim Livesey and chief financial officer Bob Smeeton join Proactive's Stephen Gunnion with details of the company's 2023 financial and operational performance. Livesey highlighted successful exploration programs in Cameroon, at the Bibemi and Mbe projects,...

1 hour, 16 minutes ago